JAMA Otolaryngol Head Neck Surg:头颈癌患者放疗和顺铂化疗后听力损失预测研究

2019-12-03 AlexYang MedSci原创

在头颈癌患者进行治疗之前,进行术后准确、易行的听力损失预测对患者进行治疗决定是必要的信息。最近,有研究人员对头颈癌患者开发了一种预测放疗后和/或者顺铂化疗后预测听力损失的模型。研究包括了242名头颈癌患者(482只耳朵,56名女性,平均年龄60(10)岁),并进行了回顾性的群体研究。所有包括在研究中的患者接受了放疗,105名患者(43.4%)接受了顺铂化疗。平均总的顺铂剂量为298(109)mg/

在头颈癌患者进行治疗之前,进行术后准确、易行的听力损失预测对患者进行治疗决定是必要的信息。最近,有研究人员对头颈癌患者开发了一种预测放疗后和/或者顺铂化疗后预测听力损失的模型。

研究包括了242名头颈癌患者(482只耳朵,56名女性,平均年龄60(10)岁),并进行了回顾性的群体研究。所有包括在研究中的患者接受了放疗,105名患者(43.4%)接受了顺铂化疗。平均总的顺铂剂量为298(109)mg/m2。患者的耳朵接受的平均耳蜗放射剂量为15(13)Gy。预测模型的固定效应预测与术后纯音听觉均值变化的77%一致(95%CI, 73%-81%)。该预测模型在预测观察的术后纯音听觉均值大于35 dB(AUC, 0.85)患者中,敏感性和特异性分别为80%和75%。

最后,研究人员指出,他们的研究首次开发了能够准确预测头颈癌患者术后听力的模型,并且他们的模型在治疗前和开始时是可以应用在临床上的。他们的研究也确认了耳蜗接触顺铂化疗和放疗与听力损失有关。他们的研究也激发了对耳毒性的进一步研究,从而更好的理解头颈癌治疗中的副作用情况。

原始出处:

Schuette A, Lander DP, Kallogjeri D et al. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 21 Nov 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
    2020-10-07 ms1000001157291874

    研究新颖,受益良多

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
    2019-12-05 drj2006
  5. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
    2019-12-05 ysjykql
  6. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
    2019-12-03 14794e5bm67(暂无昵称)

    研究新颖,受益良多

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
    2019-12-03 14794e5bm67(暂无昵称)

    研究新颖,受益良多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
    2019-12-03 14794e5bm67(暂无昵称)

    研究新颖,受益良多

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=890502, encodeId=27d68905026a, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210507/fc1e1781be8741f8b842f21ad3344ad6/d868caa04cb94ea9903984a25ea07fd6.jpg, createdBy=4bc85397157, createdName=ms1000001157291874, createdTime=Wed Oct 07 14:20:18 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri Jan 24 08:38:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044114, encodeId=56d7204411442, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 03 02:38:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490074, encodeId=df5114900e4dc, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306461, encodeId=e1fb130646125, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295900, encodeId=0e221295900f9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Dec 05 04:38:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376443, encodeId=c9bc3e644388, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:09 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376442, encodeId=e8723e64426b, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:05 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376441, encodeId=7f353e644129, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:03 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376440, encodeId=54aa3e6440c8, content=研究新颖,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Tue Dec 03 18:49:00 CST 2019, time=2019-12-03, status=1, ipAttribution=)]
    2019-12-03 14794e5bm67(暂无昵称)

    研究新颖,受益良多

    0

相关资讯

盘点:近期听力损失研究盘点

听力损失(hearing loss)又称聋度(deafness)或听力级(hearing level)。是人耳在某一频率的听阈比正常听阈高出的分贝数。由于年龄关系产生的听力损失称为老年性耳聋;由于社会环境噪声(年龄、职业性噪声和疾病等影响除外)产生的听力损失称为社会性耳聋;职业性噪声导致的听力损失称为噪声性耳聋。梅斯医学小编整理了近期听力损失的研究进展,与大家一起分享学习!【1】Int J P

盘点:听力损失治疗盘点

【1】Eur Arch Otorhinolaryngol:内镜下镫骨切开术的安全性和听力结果研究 耳硬化症最广泛接受使用的疗法是局部麻醉或者全身麻醉条件下的微观镫骨手术。最近,有研究人员阐述了内窥镜镫骨手术的手术步骤,并评估了听觉和手术结果。研究人员招募了那些在2014年11月到2018年12月之间因镫骨切开术而进行内窥镜手术或翻修手术的患者。研究人员发现,在调查期间,共进行了181

Acta Paediatr:单边或者轻度到中度双边听力损失儿童应该进行神经发育问题的筛选

最近,有研究人员评估了9-12岁单边或者轻度到中度双边听力损失儿童中语言和其他神经发育问题的比率和重叠程度情况。58名符合条件的儿童中24名由看护者照料,他们出生在2004年-2007年,并完成了一个综合筛查神经发育问题的调查问卷。在这24名儿童中,21名进行了CELF-4评估。那些在调查问卷中明确具有神经发育问题的儿童的父母也被邀请进行临床神经评估。研究发现,在24名儿童中,13名(54%)筛选

Clin Otolaryngol:传导性听力损失对平衡影响研究

平衡是一个复杂的过程,涉及多重的感知、运动和生物力学过程的协调。平衡功能在听力损失患者中可能受损,并且是由于听力损失的病理所致。最近,有研究人员调查了模拟的传导性听力损失对维持身体平衡能力的影响情况。研究包括了20名听力正常的受试者,年龄20-30岁。他们在用耳塞堵塞外耳道前后进行了电脑化的动态姿势测试,从而达到模仿40dB传导性听力损失的效果。研究测试了18名女性和2名男性。平均的CHL为40±

Int J Audiol:重度到永久性感觉神经性听力损失老年患者与正常听力同龄老年人认知差异分析

最近,有研究人员对重度到永久性感觉神经性听力损失老年患者的认知表现以及耳蜗移植使用后的认知表现与同龄正常老年人进行比较。研究是一个前瞻性的案例对照匹配研究,研究包括了30名年龄在60岁到80岁的老年人,其患有双边重度到永久性感觉神经性听力损失,且有耳蜗移植使用。匹配的对照组包括了30名听力正常的同龄人。研究发现,建构性练习与回忆、连线测试A与Stroop测试在两个小组之间没有显著差异。然而,钟面画

Sci Rep:听力能力不是老年人住院护理的一个风险因子

在许多国家,老年人住院护理(ARC)需求均超过了其自身承受能力,其中包括了新西兰。因此,鉴定能够预防或者延迟ARC接入的可改变因素具有重要的国际意义。听力损伤是老年人中常见的疾病,监管目前的证据仍旧比较模糊,但仍是一个重要的预测因子。最近,有研究人员使用最大的国家数据库,对具有标准家庭护理评估的34277名老年人进行了竞争风险回顾分析,时间为2012年7月到2014年5月,年龄≥65岁,并且在评估